Advancing cerebrospinal fluid biomarker discovery by mass spectrometry

Cerebrospinal fluid (CSF) is an important source of biomarkers of neurodegenerative diseases [1]. Reflecting biochemical processes in the brain, proteins in the CSF may reveal clues to disease mechanisms. As new disease-modifying therapies are being developed, there is an increased need for markers that enable earlier, more accurate diagnosis and provide means to monitor disease progression and response to treatment. While, until recently, CSF biomarker research focused on relatively few proteins derived from genetic mutations or pathological manifestations in the brain, advances in MS have opened up possibilities for discovering and developing new biomarkers. Click here to view the full...